As Kamala Harris’s 2024 presidential campaign gains momentum, her aggressive stance on Medicare expansion and potentially eliminating private health insurance is drawing significant attention. Harris has been a long-standing advocate for Medicare for All, including supporting Bernie Sanders’ bill to eliminate private insurance for all age groups.
The ambitious plan by Kamala Harris could have profound implications for individual healthcare costs, such as out-of-pocket expenses for retirees and investment opportunities across the healthcare sector. This article delves into the ramifications for major medical stocks like CVS Health Corporation (CVS), Teladoc Health, Inc. (TDOC), Abbott Laboratories (ABT), and Johnson & Johnson (JNJ).
Kamala Harris’ Stance on Medicare Expansion
Over the years, Harris has consistently championed Medicare for all, aligning with Senator Bernie Sanders’s vision of a single-payer healthcare system. Her proposal envisions a significant expansion of Medicare, extending coverage to all Americans and eliminating the need for private health insurance. She has remained among the more outspoken Democratic politicians promoting government-led insurance programs.
In 2017, Harris was the first senator to co-sponsor Bernie Sanders’s bill, the Medicare for All Act of 2017. If enacted, that bill would abolish private health insurance for all age groups, including Medicare beneficiaries, and replace it with a government-run single-payer system to benefit every resident of the United States, including undocumented immigrants.
On January 21, 2019, Harris announced her intention to run for the 2020 Democratic nomination for President. A few days later, during a CNN town hall event in Iowa, she elaborated on her reasons for aiming to eliminate “inhumane” private insurance.
“Well, listen, the idea is that everyone gets access to medical care, and you don’t have to go through the process of going through an insurance company, having them give you approval, going through the paperwork, all of the delay that may require,” Harris said. “Who of us has not had that situation where you’ve got to wait for approval, and the doctor says, well, I don’t know if your insurance company is going to cover this. Let’s eliminate all of that. Let’s move on.”
Although Harris reversed herself multiple times in 2019, she remained committed to the broader goal of Medicare for All. On July 29, 2019, Harris unveiled a detailed outline of what she termed “my plan for Medicare for all,” which featured significant differences from both Bernie Sanders’s version and the various versions she had previously endorsed.
Like the Sanders bill, Harris’s new plan would eliminate employer-sponsored insurance, Affordable Care Act exchange plans, Medicaid, and other existing programs, replacing them with Medicare-based coverage. However, unlike Sanders’s proposal, Harris’ July 2019 plan would permit private insurers to continue offering Medicare Advantage-style coverage, albeit with lower reimbursement rates compared to traditional Medicare.
Additionally, while Sanders’s bill includes a four-year transition period to single-payer healthcare, Harris’s plan proposed a 10-year transition to the new system.
If Kamala Harris wins the 2024 presidential election, she is expected to advance her Medicare for All agenda, which could lead to significant changes in the U.S. healthcare system.
“She is a strong advocate for both [Social Security and Medicare] and is keen on expanding them,” stated Aaron Cirksena, CEO of MDRN Capital, a retirement planning firm. “This includes protecting benefits from any cuts and expanding the reach of coverage.”
“These plans may mean an increase in government spending and taxes, likely for upper-class earners,” Cirksena explained. “It may also mean lower out-of-pocket healthcare expenses and easier access to services for retirees.”
Implications for Healthcare Stocks
The proposed Medicare for all plan could lead to a significant restructuring of the healthcare sector, with wide-ranging economic implications. Expanding Medicare would likely result in a surge in government healthcare spending. It could also affect individual costs, including out-of-pocket expenses for retirees.
Moreover, the shift towards a more government-controlled healthcare system may create new investment opportunities in areas such as telemedicine, retail pharmacy services, and health technology. Companies that can adapt to the changing landscape and align with government priorities may find growth opportunities.
Insurers: CVS Health Corporation (CVS) is a prominent health solutions company broadening medical access for millions of people globally. The company provides private insurance through its subsidiary, Aetna, which offers a range of insurance products, including individual and family health plans, employer-sponsored plans, and Medicare Advantage plans.
The potential reduction in the role of private insurance under the Harris administration could impact CVS’ insurance operations, including Aetna. It might lead CVS to pivot more towards its retail pharmacy and healthcare services, influencing its strategic direction. CVS Health stands to benefit considerably from the proposed Medicare expansion, potentially boosting the company’s profitability and growth.
While there are several opportunities for CVS to benefit from Medicare expansion, the actual impact would depend on the specifics of the policy changes and how the company adapts to and capitalizes on these changes.
Telehealth Providers: Teladoc Health, Inc. (TDOC) can benefit from increased demand for telemedicine services under a Medicare for all plan. The company operates through Teladoc Health Integrated Care and BetterHelp segments, providing virtual healthcare services, including general medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.
As access to healthcare is likely to become broader under Kamala Harris’ proposed plan, TDOC is positioned to cater to a growing patient base seeking virtual medical services, driving the company’s revenue streams and market reach.
Pharmaceutical and Medical Device Companies: Johnson & Johnson (JNJ) is a global leader in the healthcare industry, known for its extensive range of products spanning pharmaceuticals, medical devices, and consumer health. Johnson & Johnson stands to gain from Harris’ Medicare for All plan through increased demand for its healthcare products, as well as potential opportunities for strategic partnerships and government contracts.
The expanded Medicare coverage could enhance J&J’s market reach and provide a more stable financial environment for its diverse healthcare offerings.
Abbott Laboratories (ABT), another key player in medical devices and branded generic pharmaceuticals, could benefit from Kamala Harris’ proposed plan. Increased Medicare coverage might drive higher demand for medical devices and diagnostic tests. Abbott may also find opportunities for collaboration with government agencies and healthcare systems to integrate its solutions into the expanded Medicare framework, potentially enhancing its market presence.
Bottom Line
Vice President Kamala Harris’ Medicare for All proposed plan represents a transformative vision for the U.S. healthcare system, potentially reshaping individual healthcare costs and impacting major healthcare stocks. The expansion of Medicare promises reduced out-of-pocket expenses and broader coverage and provides opportunities for healthcare companies like CVS, TDOC, ABT, and JNJ.
Investors should stay attuned to the evolving policy landscape in the healthcare sector and consider how these developments might influence investment strategies and market dynamics.
